Skip to content

The effects of coenzyme Q10 supplementation in diabetic hemodialysis patients

The effects of coenzyme Q10 supplementation on anthropometric indices, lipid profiles, glycemic control, insulin resistance and fatigue status in diabetic hemodialysis patients: A Randomized, Double Blind, Placebo Controlled Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20170202032367N13
Enrollment
48
Registered
2025-12-19
Start date
2026-04-09
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease. Chronic kidney disease, stage 5

Interventions

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age between 30 and 60 years Undergoing regular hemodialysis (for at least the past 6 months, three sessions per week) Body mass index (BMI) greater than 18.5 and less than 30 kg/m² No hospitalization during the past 3 months Willingness to participate and cooperate in the study

Exclusion criteria

Exclusion criteria: Blood pressure higher than 160/100 mmHg Blood pressure lower than 100/60 mmHg Receiving enteral or parenteral nutritional support Use of glucocorticoids, antibiotics, Fluvoxamine, anti-inflammatory drugs (NSAIDs) or warfarin Smoking History of any autoimmune diseases, thyroid disorders, malignancies Use of antioxidant supplements within the past 3 months Kidney transplantation less than 6 months prior to study enrollment Hospitalization within the past 3 months Pregnancy, intention to become pregnant within the next 6 months, or breastfeeding

Design outcomes

Primary

MeasureTime frame
Serum levels of Glycemic control (HbA1C, FBS and fasting insulin). Timepoint: Before the intervention and 12 weeks later. Method of measurement: Diagnostic kits.;Insulin resistance indices (HOMA-IR, HOMA-beta, TyG, QUICKI). Timepoint: Before the intervention and 12 weeks later. Method of measurement: Calculated using the relevant formula.

Secondary

MeasureTime frame
Anthropometric indices (body weight, body mass index, skeletal muscle mass index, fat mass, extracellular water to total body water ratio, and phase angle). Timepoint: Before the intervention and 12 weeks later. Method of measurement: Anea BIA 1204 body composition analysis.;Serum levels of lipid parameters (T.G, T.C, LDL, HDL). Timepoint: Before the intervention and 12 weeks later. Method of measurement: spectrophotometry method.;Fatigue status. Timepoint: Before the intervention and 12 weeks later. Method of measurement: Completion of the Fatigue Assessment Scale (FAS) questionnaire.;Systolic and diastolic blood pressure. Timepoint: Before the intervention and 12 weeks later. Method of measurement: Sphygmomanometer and calibrated stethoscope.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossien Imani

Tehran University of Medical Sciences

h_imani@sina.tums.ac.ir+9821889900285

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026